Informed Consent Process
Informed consent ensures that clinical trial participants understand the risks, benefits, and alternatives before voluntarily agreeing to participate.
## What Is Informed Consent?
Informed consent is the process by which a potential clinical trial participant receives comprehensive information about the study, demonstrates understanding of that information, and voluntarily agrees to participate. It is not merely a signature on a document -- it is an ongoing dialogue between the investigator and participant throughout the trial.
## Regulatory Foundation
The Nuremberg Code (1947), the Declaration of Helsinki (1964, revised 2013), and the Belmont Report (1979) established the ethical principles underlying informed consent. In the United States, FDA regulations (21 CFR 50) and the Common Rule (45 CFR 46) codify specific requirements. The International Council for Harmonisation's Good Clinical Practice (ICH-GCP E6) provides the global standard.
## Required Elements
The informed consent document must include:
- The purpose of the research and expected duration of participation
- A description of all study procedures, including which are experimental
- Reasonably foreseeable risks and discomforts
- Potential benefits to the participant or to others
- Available alternative treatments
- How confidentiality of records will be maintained
- Whether compensation is available if injury occurs
- Contact information for questions about the study, participant rights, and research-related injuries
- A statement that participation is voluntary and may be withdrawn at any time without penalty
## Vulnerable Populations
Special protections exist for populations with diminished capacity to provide autonomous consent:
- **Children**: Require parental permission plus the child's assent (age-appropriate agreement). Adolescents capable of understanding may provide their own consent in some jurisdictions.
- **Cognitively impaired individuals**: Require a legally authorized representative to consent on their behalf, with re-consent if capacity improves.
- **Prisoners**: Additional IRB oversight to ensure participation is not coerced by the institutional environment.
- **Pregnant women**: Consent must address risks to both the woman and the fetus.
## Ongoing Consent
Informed consent is not a single event. Investigators must communicate significant new information (new risks, protocol changes, or safety findings from other studies) to participants throughout the trial. Participants may withdraw consent at any time without affecting their standard medical care.
## Electronic Consent
The FDA permits electronic informed consent (eConsent) using multimedia presentations, interactive quizzes, and electronic signatures. eConsent can improve participant comprehension, particularly for complex protocols, while maintaining regulatory compliance.
## Key Takeaways
- Informed consent is an ongoing process, not just a signed document
- All required elements must be presented in language the participant can understand
- Vulnerable populations receive additional protections and oversight
- New safety information must be communicated to participants throughout the trial
- Electronic consent is permitted and may improve comprehension